EDAP is undertaking a Phase III study to further evaluate the therapy in reducing acute pelvic pain associated with DIE. Credit: Chinnapong/ Shutterstock.com.

EDAP TMS, a developer of invasive medical devices, has received the US Food and Drug Administration’s (FDA) breakthrough device designation for its Focal One platform to treat deep infiltrating endometriosis (DIE).

The FDA approved the Focal One high-intensity focused ultrasound (HIFU) system for prostatic tissue ablation in June 2018.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A non-invasive, robotic ablative procedure, Focal One HIFU uses a high-intensity ultrasound probe for delivering tissue devitalisation by using acoustic cavitation and thermal ablation.

Positive results from the Phase II Endo-HIFU-1R study, which included 60 participants, were pivotal in EDAP’s FDA submission for the breakthrough device designation.

The study demonstrated significant symptom reduction and quality of life improvements post-treatment, with a notable decrease in lesion volume confirmed by MRI at six months.

EDAP is undertaking a Phase III study (Endo-HIFU-R2) to further evaluate Focal One HIFU therapy in reducing acute pelvic pain associated with DIE.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company anticipates results from this randomised, double-blind trial in the latter half of 2024. The last patient was treated earlier this year, as part of the study.

EDAP TMS CEO Ryan Rhodes said: “Receiving breakthrough device designation from the FDA represents a major milestone and reinforces our commitment to expand the use of Focal One Robotic HIFU technology to treat other patient conditions beyond prostate disease.

“This designation reflects the FDA’s recognition that deep infiltrating endometriosis remains a significant unmet medical need in women’s health with few treatment alternatives. By expanding our proprietary robotic HIFU technology, we aim to provide women with a safe and effective treatment option that is significantly less invasive and less morbid than conventional surgical approaches.”